Abstract
Monoamine oxidase inhibitors have been used in Psychiatric disorders for many years. However, due to the toxic side effects of the drugs they are often replaced by the tri- and tetracyclic antidepressants.
Selective monoamine oxidase inhibitors like deprenyl, however, have been tried with success as adjuvant therapy in Parkinson’s disease and depression because of their ability to inhibit dopamine oxidation. Perhaps their greatest advantage is their lack of pressor response.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M. B. H.: Implications of combined treatment with Madopar and L-deprenyl in Parkinson’s disease. A long term study. Lancet 1, 439–443 (1977).
Birkmayer, W., Riederer, P., Youdim, M. B. H.: Deprenyl and Parkinson’s disease. In: Clinical Neuropharmacology (Klawans, H., ed.). New York: Raven Press. In press.
Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: The potentiation of the anti-akinetic effects after L-Dopa treatment by an inhibitor of MAO-B, deprenil. J. Neural Transm. 36, 303–326 (1975).
Collins, G. G. S., Sandler, M., Williams, E. D., Youdim, M. B. H.: Multiple forms of human brain mitochondriol monoamine oxidase. Nature 225, 817–820 (1970).
Eisworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K. M., Stern, G. M., Kumar, P.: Deprenyl administration in man. A selective monoamine oxidase inhibitor without the “cheese effect”. Psychopharmacologia 57, 33–38 (1978).
Einberg, J., Sabbagh, A., Youdim, M. B. H.: Pharmacology of selective acetylenic suicide inhibitors of monoamine oxidase. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).
Green, A. R., Mitchell, B., Tordoff, A., Youdim, M. B. H.: Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytrypt- amine. Brit. J. Pharmacol. 60, 343–349 (1977).
Green, A. R., Youdim, M. B. H.: Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamineconcentration in rat brain and hyperactivity following tryptophan administration. Brit. J. Pharmacol. 55, 415–422 (1975).
Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. Af., Eisworth, J. D., Sandler, Af., Youdim, Äf..: Deprenyl in Parkinson’s disease. Lancet 2, 791–796 (1977).
Mendlewicz, J., Youdim, M. B. H.: Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO “type B” inhibitor. J. Neural Transm. 43 279–286 (1978).
Riederer, P., Youdim, M. B. H., Rausch, W. D., Birkmayer, W., Jellinger, K., Seemann, DOn the mode of action of L-deprenyl in the human central nervous system. J. Neural Transm. 43, 217–226 (1978).
Youdim, M. B. H.: The use of selective monoamine oxidase “type B” inhibitors in the treatment of Parkinson’s disease. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).
Youdim, M. B. HCollins, G. G. S., Sandler, M.: Multiple forms of rat brain monoamine oxidase. Nature 223, 626–628 (1969).
Youdim, M. B. H., Collins, G. G., Sandler, M.: Monoamine oxidase: Multiple forms and selective inhibition. Biochem. J. 121, 34–36 (1971).
Youdim, M. B. H., Collins, G. G. S., Sandler, M., Bevan Jones, A. B., Pare, C. M. B., Nicholson, W.J, Human brain monoamine oxidase multiple forms and selective inhibitors. Nature 236, 225–228 (1972).
Youdim, M. B. H., Green, A. R., Grahame-Smith, D. GThe role of 5-hydroxytryptamine, dopamine and MAO in the production of hyperactivity Syndrome. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 155–162. Basle: Editiones Roche. 1976.
Youdim, M. B. H., Mendlewicz, J.; Monoamine oxidase inhibition without the “cheese effect”: Clinical and pharmacological relevance in the treatment of depression. In: Enzymes and Neurotransmitters in Mental Disease (Usdin, E., Sourkes, T. L., Youdim, M. B. H., eds.). London: J. Wiley. In press (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this chapter
Cite this chapter
Youdim, M.B.H. (1980). Monoamine Oxidase Inhibitors as Anti-Depressant Drugs and as Adjunct to L-Dopa Therapy of Parkinson’s Disease. In: Carlsson, A., Jellinger, K., Riederer, P. (eds) Current Topics in Extrapyramidal Disorders. Journal of Neural Transmission, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8582-7_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8582-7_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8584-1
Online ISBN: 978-3-7091-8582-7
eBook Packages: Springer Book Archive